Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02598973 · ClinicalTrials.gov registry record · NA

Effect of Exercise in Parkinsonism

A NA study of Parkinson's Disease and Drug-induced Parkinsonism, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT02598973: Completed NA study of Parkinson's Disease and Drug-induced Parkinsonism, sponsored by VA Office of Research and Development.

NCT02598973 is a NA study of Parkinson's Disease and Drug-induced Parkinsonism that has completed, run by VA Office of Research and Development. The registered enrollment target is 9 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02598973, a NA study of Parkinson's Disease and Drug-induced Parkinsonism, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

Parkinson's disease (PD) is a common neurodegenerative disorder affecting approximately 80,000 Veterans, representing a priority area for VA research. Current medicines for PD only improve symptoms, treatments that slow disease progression are needed, and earlier diagnosis of PD may be the key to their development. PD symptoms can be mimicked by medicines (most commonly antipsychotic drugs that block dopamine), and some of these patients actually have underlying "prodromal" PD that was "unmasked" years before it would have caused symptoms. This problem is increasing as these medicines are now used for common conditions including post-traumatic stress disorder and depression. The investigators will identify prodromal PD in patients with drug-induced symptoms using brain scans. These patients will be enrolled in a randomized clinical trial of aerobic exercise which slows progression in animal models of PD and has other health benefits. The investigators will measure the effect of exercise on symptoms, disease progression (using brain scans) and markers of PD risk (using blood tests). These studies will improve early PD diagnosis and potentially identify a way to slow progression of PD.

Primary Outcome

change in semi-quantitative Ioflupane-I123 uptake comparing exercise to no intervention.

Interventions

  • BEHAVIORAL Exercise

Study Locations (1)

Pennsylvania

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA - Philadelphia

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2016-02-01
Est. Completion 2022-01-31
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02598973 record still lists

NCT02598973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Exercise is the first listed.

NCT02598973 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02598973 about?

NCT02598973 is a clinical study titled "Effect of Exercise in Parkinsonism". Parkinson's disease (PD) is a common neurodegenerative disorder affecting approximately 80,000 Veterans, representing a priority area for VA research. Current medicines for PD only improve symptoms, treatments that slow disease progression are needed, and earlier diagnosis of PD may be the key to th...

What is the current status of trial NCT02598973?

This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2016-02-01. Estimated completion is 2022-01-31.

What conditions does trial NCT02598973 study?

This clinical trial studies the following conditions: Parkinson's Disease, Drug-induced Parkinsonism.

What interventions are being tested in trial NCT02598973?

The interventions under investigation include: Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT02598973?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02598973 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02598973's enrollment target sits among peer trials

9 152nd of 158 higher than 7 of 158 other Parkinson's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02598973, the US trial registry maintained by the National Library of Medicine. NCT02598973 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.